Recent Updates
Recently added Catalysts
ALXO

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

Wednesday, December 9, 2020 BiopharmaWatch Research 1 min read
Add on Google
Key Takeaway: ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock

BiopharmaWatch Analysis

From our catalyst data and publicly available data · not financial advice
Best trade, last catalyst
+102%
120-day peak, hindsight
Typical move
7.9%
average across 6 past catalysts
Cash runway
~25 mo
Minimal dilution risk
Lead asset
ALX2004
Phase 1 · NSCLC (Advanced Non-small Cell Lung Cancer)

Full Press Release Details

ALX Oncology Announces Pricing of Upsized Public Offering of Common Stock.
ShareAdd on Google
Tags: ALXO Viatris Investor Conferences Healthcare investor conferences healthcare conferences UBS Global Healthcare
Last updated: Dec 9, 2020

Biotech snapshot

Cash runway
$138M liquidity · $5M/mo burn
~25 mo
Minimal dilution risk
Lead asset
ALX2004Phase 1
NSCLC (Advanced Non-small Cell Lung Cancer) →

Catalyst track record

+102%
best trade around ALXO's most recent catalyst

Peak hindsight return over a 120-day window, across 6 tracked FDA/PDUFA catalysts for ALXO.

See every catalyst's timing & PoA →